Background/Aims: Type 2 resistant starch from high-amylose maize (HAM-RS2) is associated with increased fermentation, increased expression of proglucagon (gene for GLP-1) and peptide YY (PYY) genes in the large intestine, and improved health. To determine what other genes are up- or downregulated with feeding of HAM-RS2, a microarray was performed. Methods: Adult, male Sprague Dawley rats were fed one of the following three diets for a 4-week study period: cornstarch control (CC, 3.74 kcal/g), dietary energy density control (EC, 3.27 kcal/g), and 30% HAM-RS2 (RS, 3.27 kcal/g). Rat microarray with ∼27,000 genes and validation of 94 representative genes with multiple qPCR were used to determine gene expression in total RNA extracts of cecal cells from rats. The RS versus EC comparison tested effects of fermentation as energy density of the diet was controlled. Results: For the RS versus EC comparison, 86% of the genes were validated from the microarray and the expression indicates promotion of cell growth, proliferation, differentiation, and apoptosis. Gut hormones GLP-1 and PYY were increased. Conclusions: Gene expression results predict improved structure and function of the GI tract. Production of gut hormones may promote healthy functions beyond the GI tract.

Keywords:
High-amylose maize, Resistant starch, Microarray, Validation, Cecal cells, Gastrointestinal tract
1.
Brown IL: Applications and uses of resistant starch. J AOAC Int 2004;87:727–732.
2.
Cassidy A, Bingham SA, Cummings JH: Starch intake and colorectal cancer risk: an international comparison. Br J Cancer 1994;69:937–942.
3.
de Deckere EA, Kloots WJ, van Amelsvoort JM: Resistant starch decreases serum total cholesterol and triacylglycerol concentrations in rats. J Nutr 1993;123:2142–2151.
4.
Higgins JA: Resistant starch: metabolic effects and potential health benefits. J AOAC Int 2004;87:761–768.
5.
Keenan MJ, Zhou J, McCutcheon KL, Raggio AM, Bateman HG, Todd E, Jones CK, Tulley RT, Melton S, Martin RJ, Hegsted M: Effects of resistant starch, a non-digestible fermentable fiber, on reducing body fat. Obesity (Silver Spring) 2006;14:1523–1534.
6.
Robertson MD, Bickerton AS, Dennis AL, Vidal H, Frayn KN: Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. Am J Clin Nutr 2005;82:559–567.
7.
Robertson MD, Currie JM, Morgan LM, Jewell DP, Frayn KN: Prior short-term consumption of resistant starch enhances postprandial insulin sensitivity in healthy subjects. Diabetologia 2003;46:659–665.
8.
Shen L, Keenan MJ, Raggio A, Williams C, Martin RJ: Dietary-resistant starch improves maternal glycemic control in Goto-Kakazaki rat. Mol Nutr Food Res 2011;55:1499–1508.
9.
Shen L, Keenan MJ, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Zhou J: Dietary resistant starch increases hypothalamic POMC expression in rats. Obesity (Silver Spring) 2009;17:40–45.
10.
Tulley RT, Appel MJ, Enos TG, Hegsted M, McCutcheon KL, Zhou J, Raggio AM, Jeffcoat R, Birkett A, Martin RJ, Keenan MJ: Comparative methodologies for measuring metabolizable energy of various types of resistant high amylose corn starch. J Agric Food Chem 2009;57:8474–8479.
11.
Zhou J, Hegsted M, McCutcheon KL, Keenan MJ, Xi X, Raggio AM, Martin RJ: Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. Obesity (Silver Spring) 2006;14:683–689.
12.
Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S, Hegsted M, Keenan MJ: Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 2008;295:E1160–E1166.
13.
Zhou J, Martin RJ, Tulley RT, Raggio AM, Shen L, Lissy E, McCutcheon K, Keenan MJ: Failure to ferment dietary resistant starch in specific mouse models of obesity results in no body fat loss. J Agric Food Chem 2009;57:8844–8851.
14.
Sajilata MG, Singhai RS, Kulkarni PR: Resistant starch: a review. Compr Rev Food Sci Food Saf 2006;5:1–17.
15.
Reeves PG, Nielsen FH, Fahey GC Jr: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939–1951.
16.
Behall KM, Howe JC: Resistant starch as energy. J Am Coll Nutr 1996;15:248–254.
17.
Englyst HN, Kingman SM, Hudson GJ, Cummings JH: Measurement of resistant starch in vitro and in vivo. Br J Nutr 1996;75:749–755.
18.
Chen Q, Swist E, Beckstead J, Green J, Matias F, Roberts J, Qiao C, Raju J, Brooks SP, Scoggan KA: Dietary fructooligosaccharides and wheat bran elicit specific and dose-dependent gene expression profiles in the proximal colon epithelia of healthy Fischer 344 rats. J Nutr 2011;141:790–797.
19.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–408.
20.
Howard MD, Gordon DT, Pace LW, Garleb KA, Kerley MS: Effects of dietary supplementation with fructooligosaccharides on colonic microbiota populations and epithelial cell proliferation in neonatal pigs. J Pediatr Gastroenterol Nutr 1995;21:297–303.
21.
Rust WL, Carper SW, Plopper GE: The promise of integrins as effective targets for anticancer agents. J Biomed Biotechnol 2002;2:124–130.
22.
Matsumoto K, Asano T, Endo T: Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton. Oncogene 1997;15:2409–2417.
23.
Bleuming SA, He XC, Kodach LL, Hardwick JC, Koopman FA, Ten Kate FJ, van Deventer SJ, Hommes DW, Peppelenbosch MP, Offerhaus GJ, et al: Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer Res 2007;67:8149–8155.
24.
Kim GS, Choi YK, Song SS, Kim WK, Han BH: MKP-1 contributes to oxidative stress-induced apoptosis via inactivation of ERK1/2 in SH-SY5Y cells. Biochem Biophys Res Commun 2005;338:1732–1738.
25.
Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, Skoko JJ 3rd, Lazo JS: A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther 2008;7:330–340.
26.
Vogt A, Lazo JS: Discovery of protein kinase phosphatase inhibitors. Methods Mol Biol 2007;356:389–400.
27.
Shao J SH: Amphiregulin promotes intestinal epithelial regeneration: roles of intestinal subepithelia myofibroblasts. Endocrinology 2010;151:3728–3737.
28.
Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1990;10:1969–1981.
29.
Billings SD, Southall MD, Li T, Cook PW, Baldridge L, Moores WB, Spandau DF, Foley JG, Travers JB: Amphiregulin overexpression results in rapidly growing keratinocytic tumors: an in vivo xenograft model of keratoacanthoma. Am J Pathol 2003;163:2451–2458.
30.
Le Leu RK, Brown IL, Hu Y, Young GP: Effect of resistant starch on genotoxin-induced apoptosis, colonic epithelium, and lumenal contents in rats. Carcinogenesis 2003;24:1347–1352.
31.
Dinarello CA: The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314–1325.
32.
Chen S, Law CS, Gardner DG: Vitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J Steroid Biochem Mol Biol 2010;118:135–141.
33.
Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, et al: Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006;12:1056–1064.
34.
Martinon F, Tschopp J: Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007;14:10–22.
35.
Aggarwal BB, Aiyer RA, Pennica D, Gray PW, Goeddel DV: Human tumour necrosis factors: structure and receptor interactions. Ciba Found Symp 1987;131:39–51.
36.
Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634–1635.
37.
Wajant H: Death receptors. Essays Biochem 2003;39:53–71.
38.
Hershey JW: Translational control in mammalian cells. Annu Rev Biochem 1991;60:717–755.
39.
Shirakata Y, Komurasaki T, Toyoda H, Hanakawa Y, Yamasaki K, Tokumaru S, Sayama K, Hashimoto K: Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 2000;275:5748–5753.
40.
Zhu Z KJ, Friess H, Wang L, Zimmerman A, Yarden Y, Buchler MW, Korc M: Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000;273:1019–1024.
41.
Zerbini LF, Libermann TA: Life and death in cancer. GADD45 alpha and gamma are critical regulators of NF-kappaB mediated escape from programmed cell death. Cell Cycle 2005;4:18–20.
42.
Zerbini LF, Libermann TA: GADD45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets. Clin Cancer Res 2005;11:6409–6413.
43.
Li L, Hu JS, Olson EN: Different members of the jun proto-oncogene family exhibit distinct patterns of expression in response to type beta transforming growth factor. J Biol Chem 1990;265:1556–1562.
44.
Wilkinson DG, Bhatt S, Ryseck RP, Bravo R: Tissue-specific expression of c-jun and junB during organogenesis in the mouse. Development 1989;106:465–471.
45.
Gurzov EN, Bakiri L, Alfaro JM, Wagner EF, Izquierdo M: Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene 2008;27:641–652.
46.
Fritz G, Kaina B: Ras-related GTPase Rhob represses NF-kappaB signaling. J Biol Chem 2001;276:3115–3122.
47.
Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG: Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005;23:543–548.
48.
Zhang Z, Zhang R: Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J 2008;27:852–864.
49.
Lang KJ, Kappel A, Goodall GJ: Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 2002;13:1792–1801.
50.
Holmes K Roberts OL, Thomas AM, Cross MJ: Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular Signal 2007;19:2003–2012.
51.
Rossi F, Bertone C, Petricca S, Santiemma V: Adrenomedullin antagonizes angiotensin II-stimulated proliferation of human aortic smooth muscle cells. Peptides 2006;27:2935–2941.
52.
Chen BP, Liang G, Whelan J, Hai T: ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem 1994;269:15819–15826.
53.
Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O: Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer 2010;10:668.
54.
Hagiya K, Yasunaga J, Satou Y, Ohshima K, Matsuoka M: ATF3; an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells. Retrovirology 2011;8:19.
55.
Pulford DJ, Hayes JD: Characterization of the rat glutathione S-transferase Yc2 subunit gene, GSTA5: identification of a putative antioxidant-responsive element in the 5′-flanking region of rat GSTA5 that may mediate chemoprotection against aflatoxin B1. Biochem J 1996;318:75–84.
56.
Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S: The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000;350:219–227.
57.
Franchini GR, Curto LM, Caramelo JJ, Delfino JM: Dissection of a beta-barrel motif leads to a functional dimer: the case of the intestinal fatty acid binding protein. Protein Sci 2009;18:2592–2602.
58.
Bonne A, Gosele C, den Bieman M, Gillissen G, Kreitler T, Pravenec M, Kren V, van Lith H, van Zutphen B: Sequencing and chromosomal localization of Fabp6 and an intronless Fabp6 segment in the rat. Mol Biol Rep 2003;30:173–176.
59.
Hadjiagapiou C, Schmidt L, Dudeja PK, Layden TJ, Ramaswamy K: Mechanism(s) of butyrate transport in Caco-2 cells: role of monocarboxylate transporter 1. Am J Physiol Gastrointest Liver Physiol 2000;279:G775–G780.
60.
Saksena S, Dwivedi A, Gill RK, Singla A, Alrefai WA, Malakooti J, Ramaswamy K, Dudeja PK: PKC-dependent stimulation of the human MCT1 promoter involves transcription factor AP2. Am J Physiol Gastrointest Liver Physiol 2009;296:G275–G283.
61.
Hori M, Satoh M, Furukawa K, Sakamoto Y, Hakamata H, Komohara Y, Takeya M, Sasaki Y, Miyazaki A, Horiuchi S: Acyl-coenzyme A: cholesterol acyltransferase-2 (ACAT-2) is responsible for elevated intestinal ACAT activity in diabetic rats. Arterioscler Thromb Vasc Biol 2004;24:1689–1695.
62.
Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H: Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 2011;108:3270–3275.
63.
Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 1999;20:876–913.
64.
Kislauskis E, Bullock B, McNeil S, Dobner PR: The rat gene encoding neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution of exon sequences. J Biol Chem 1988;263:4963–4968.
65.
Degolier TF, Duke GE, Carraway RE: Neurotensin decreases pepsin output and gastrointestinal motility in chickens. Poult Sci 1997;76:1435–1439.
66.
Boey D, Sainsbury A, Herzog H: The role of peptide YY in regulating glucose homeostasis. Peptides 2007;28:390–395.
67.
Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262–269.
68.
Boey D, Heilbronn L, Sainsbury A, Laybutt R, Kriketos A, Herzog H, Campbell LV: Low serum PYY is linked to insulin resistance in first-degree relatives of subjects with type 2 diabetes. Neuropeptides 2006;40:317–324.
69.
Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, et al: Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 2002;418:650–654.
70.
Lee M, Wardlaw SL: The central melanocortin system and the regulation of energy balance. Front Biosci 2007;12:3994–4010.
71.
Ma X, Bruning J, Ashcroft FM: Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 2007;27:7125–7129.
72.
Osaka T, Endo M, Yamakawa M, Inoue S: Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 2005;26:1623–1631.
73.
Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J: Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr 2006;84:556–560.
74.
Usui D, Yamaguchi-Shima N, Okada S, Shimizu T, Wakiguchi H, Yokotani K: Selective activation of the sympathetic ganglia by centrally administered corticotropin-releasing factor in rats. Auton Neurosci 2009;146:111–114.
75.
Adams SH, Lei C, Jodka CM, Nikoulina SE, Hoyt JA, Gedulin B, Mack CM, Kendall ES: PYY[3–36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. J Nutr 2006;136:195–201.
76.
Fukasawa T, Murashima K, Matsumoto I, Hosono A, Ohara H, Nojiri C, Koga J, Kubota H, Kanegae M, Kaminogawa S, et al: Identification of marker genes for intestinal immunomodulating effect of a fructooligosaccharide by DNA microarray analysis. J Agric Food Chem 2007;55:3174–3179.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.